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Apolipoprotein D is a lipocalin, primarily associated with high density lipoproteins in human plasma. Its expression is induced in several
pathological and stressful conditions including growth arrest suggesting that it could act as a nonspecific stress protein. A survey of cellular
stresses shows those causing an extended growth arrest, as hydrogen peroxide and UV light increase apoD expression. Alternatively, lipo-
polysaccharide (LPS), a pro-inflammatory agonist showed a time- and dose-dependent effect on apoD expression that correlates with an increase
in proliferation. At the promoter level, NF-kB, AP-1 and APRE-3 proved to be the elements implicated in the LPS response. Colocalization of
apoDh–GFP fusion constructs with DNA and Golgi markers, immunocytochemistry of the endogenous protein and cell fractionation showed that
both serum starvation and LPS treatment caused a displacement of apoD localization. In normal conditions, apoD is mainly perinuclear but it
accumulates in cytoplasm and nucleus under these stress conditions. Since nuclear apoD appears derived from the secreted protein, it may act as an
extracellular ligand transporter as well as a transcriptional regulator depending on its location. This role of apoD inside the cell is not only
dependent of endogenous apoD but may also be provided by exogenous apoD entering the cell.
© 2007 Elsevier B.V. All rights reserved.Keywords: Apolipoprotein D; Growth arrest; Inflammation; Lipocalin; Nuclear translocation1. Introduction
Apolipoprotein D (apoD) is a member of the lipocalin
superfamily that is found associated with high-density lipopro-Abbreviations: apoD, apolipoprotein D; AP-1, activating protein 1; APRE,
acute phase responsive element; BFA, Brefeldin A; BrdU, Bromodeoxyuridine;
C/EBP, CCAAT/enhancer binding protein; CPT, camptothecin; ERE, estrogen
responsive element; FGF, fibroblast growth factor; GRE, glucocorticoid
responsive element; HDL, high density lipoprotein; LPS, lipopolysaccharide;
MOPS, 3-[N-morpholino] propane-sulphonic acid; MTS/PMS, 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tet-
razolium, inner salt/phenazine methosulfate; NF-kB, nuclear factor kappa B;
PRE, progesterone responsive element; SDR, sterol-dependent repressor; SRE,
serum responsive element; STAT3, signal transducer and activator of
transcription 3; TUNEL, Terminal deoxynucleotidyl Transferase-mediated
dUTP nick end labeling
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doi:10.1016/j.bbamcr.2007.03.007teins in the plasma of humans and other species [1–6]. Unlike
most of the other plasma apolipoproteins whose expression is
limited to the liver and/or the intestine, apoD, a 29-kDa
glycoprotein, is expressed in almost all tissues that have been
tested [5,7–13] both during adulthood and during embryonic or
postnatal development [14,15]. Although apoD has been shown
to bind a number of small hydrophobic molecules, the physio-
logical ligands of apoD have yet to be definitively identified,
and it has been proposed that apoD may have multiple tissue-
specific, physiological ligands and functions [9,16,17].
In cultured cells, apoD expression is modulated in response
to various stimuli. It can be enhanced by growth arrest and
senescence [18,19] or by other factors such as steroids [20–22],
interleukin-1α [23], 1,25-dihydroxyvitamin D3 [24], retinoic
acid [24,25], or 25-hydroxycholesterol [26]. The promoter
region of the human apoD gene contains several regulatory
elements including serum response elements (SRE) and an
alternating purine–pyrimidine stretch implicated in the response
to growth arrest [19]. It also contains acute phase, estrogens,
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stress response elements (APRE, ERE, PRE, GRE, FSE, TRE,
MRE, STRE), sterol-dependent repressor (SDR), activation
proteins 1 and 2 (AP-1, AP-2), and nuclear factor kappa B
(NF-kB) binding sites [19]. There seems to be a significant
biological role for a tight physiological regulation of apoD,
and an altered apoD expression has been reported in several
pathological conditions.
ApoD is expressed at high levels in the normal central and
peripheral nervous systems of various species [5,7–10,27].
ApoD levels are further increased in human neuropathologies
such as Alzheimer's disease, stroke, meningoencephalitis,
motor neuron disease, dementia [28], Niemann–Pick [29],
schizophrenia [30,31], Parkinson disease [32] and multiple
sclerosis [33]. ApoD is also increased in several animal models
of brain injury [34–39]. In non-neurological pathologies, apoD
protein accumulates in atherosclerotic plaques [40], in the cyst
fluid from women with breast gross cystic disease [41,42], in
various cancers and in metabolic diseases such as non-insulin-
dependent diabetes mellitus type II, obesity, and syndrome X
[for review, see [43]].
Other than the increase of apoD expression, these conditions
share the presence of inflammation, oxidative stress and
apoptosis. Inflammation is a physiological response to tissue
injury, trauma, or infection and consists of a systemic reaction to
fight further tissue damage, destroy infective organisms and
activate repair processes. Chronic inflammation is associated
with certain metabolic diseases and cancers. There is also an
inflammatory component in Alzheimer's disease, multiple
sclerosis, schizophrenia, traumatic brain injury and other
neuropathologies [44]. The long-term administration of non-
steroidal anti-inflammatory drugs (NSAIDs) or cycloxygenase
(COX) inhibitors appears to reduce the incidence, or delay the
onset, of Alzheimer's disease [45]. Both naproxen and ibuprofen
(2 NSAIDs) inhibit the aggregation of β-amyloid peptides to
senile plaques ex vivo [46]. Also, apoE may play an isoform-
specific role in mediating the systemic and brain inflammatory
responses. ApoE4 has been associated with the early onset of
Alzheimer's disease and poor prognosis in other disorders such
as multiple sclerosis [47,48]. ApoD levels in CSF and hippo-
campus increased as a function of inheritance of the apoE4 allele
[28]. Mice expressing the apoE4 allele and injected with LPS
have significantly greater systemic and brain elevations of the
pro-inflammatory cytokines TNFα and IL-6 as compared with
their apoE3 counterparts [49]. Furthermore, oxidative modifica-
tion of lipids occurs during inflammatory processes and leads to
the formation and accumulation of biologically active lipid
oxidation products that induce specific cellular reactions such as
apoptosis. Moreover, oxidative stress has long been associated
with the neuronal cell death in some neurodegenerative
conditions. It is still unclear whether oxidative stress is the
initiating event or a downstream consequence of the neurode-
generative process in Alzheimer's disease andmultiple sclerosis,
two degenerative diseases presenting apoD overexpression. The
oxidant and antioxidant defense system may also be dysfunc-
tional in schizophrenia and bipolar disorders, which also show
apoD induction [30]. Finally, oxidative stress resulting from animbalance between pro-oxidants and anti-oxidants seems to play
an important role in human breast carcinogenesis [50]. Apo-
ptosis has also been reported in situations showing apoD induc-
tion as kainate excitotoxicity, enthorinal cortex lesionning and
traumatic brain injury [37–39].
The heterogeneity of situations triggering apoD expression,
although informative about the importance of apoD, leaves us in
the dark about the primary event responsible for its induction.
Thus, any stress situationmay initiate apoD expression and it has
been suggested that apoD is a nonspecific response to different
stimuli and may be part of an antioxidant defense system [51].
The aim of this study is to determine which cellular stresses
affect apoD expression and their effect on cell viability, apop-
tosis and senescence. The incidence of some of these stresses on
apoD protein synthesis and localization is further examined.
The responsive elements at the promoter level are also explored.
Our results show that only those stresses causing an extended
growth arrest increase apoD expression. Interestingly, lipopo-
lysaccharide (LPS), a pro-inflammatory agonist in fibroblasts
showed a time- and dose-dependent effect on apoD expression
that correlates with an increase in proliferation. At the promoter
level, NF-kB, AP-1 and APRE-3 proved to be the responsive
elements. LPS exposure and growth arrest also induce a trans-
location of apoD to the nucleus.
2. Materials and methods
2.1. Cell culture
All cells were obtained from ATCC, Rockville, MD and maintained in
DMEM (Invitrogen) supplemented with 10% calf serum (NIH/3T3), in MEM
(Invitrogen) supplemented with 10% fetal calf serum (HepG2, HeLa and 293),
in RPMI (Invitrogen) supplemented with 10% fetal calf serum (U373MG and
U87). All cells were also supplemented with penicillin G (100 units/ml) and
streptomycin (100 μg/ml), maintained at 37 °C in a 5% CO2 humidified
atmosphere and were fed every 2 days with fresh medium. For the analysis of
gene expression in sparsely growing cultures (normal condition), cells were
maintained in medium supplemented with 10% calf serum and harvested at 50%
of confluence. For analysis of growth arrest, cells were incubated in 0.2% serum
when they reached 80% of confluence. Medium was changed after 24 h and cells
were harvested after 4 days.
2.2. Stress induction
Cells were plated at 50% confluency, allowed to recover 24 h then stressors
were applied as follows. Two heat and two cold shocks, one of high and another
of low intensity, were used. Cells were incubated at 42 °C for 5 h (low heat) or at
45 °C for 20 min (high heat). Cells were also exposed to 32 °C for 4 h (low cold)
or to 4 °C (high cold) for 20 min. Cells were always maintained in a humidified
atmosphere containing 5% CO2 except for the 4 °C condition were culture plates
were tightly wrapped with parafilm and refrigerated for 20 min. Cells were
allowed to recover for 6 h at 37 °C before analysis. For hypo-osmotic shock, cell
medium was reduced to 60% normosmotic strength by addition of sterile
deionized water. Cells were exposed to this hypo-osmotic condition during 2 h at
37 °C then washed with PBS and replaced in normosmotic medium for 6 h
before harvest. For hyper-osmotic conditions, cells were maintained for 4 days
in regular growth medium supplemented with 150 mMNaCl before analysis and
the medium was changed every day. Metal stress was caused by addition of
metal salts to cells (100 μM ZnCl2, 100 μM CaCl2, 50 μM MnCl2, 100 μM
MgCl2, 50 μM Alk (SO4)2, 50 μM LiCl) for 4 h at 37 °C. After this treatment,
cells were washed and were allowed to recover in fresh growth medium for 4 h at
37 °C. Oxidative stress was induced by, unless otherwise indicated, addition of
100 μM or 300 μM H2O2 (Sigma-Aldrich) to the cells for 2 h at 37 °C and cells
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stress was produced by irradiating media containing 1 μM Rose Bengal with a
500 W lamp from a fixed distance of 66 cm for 15 min. To induce apoptosis,
cells were incubated for 16 h at 37 °C with 5 or 10 μM of camptothecin (CPT,
Sigma-Aldrich) or for 8 h with 0.1 μM staurosporine (Sigma-Aldrich) in serum
free DMEM. For UV irradiation, medium and plate lids were removed and cells
were irradiated with a Phillips® Sterilamp (256 nm, 15 W) with a source-to-
target distance of 70 cm. Then, cells were incubated for an additional 16 h at
37 °C. For LPS treatment, cells were exposed to medium containing 2, 5, or
10 μg/ml of LPS (Sigma-Aldrich) for 4 days or as indicated. Medium was
refreshed every day. Alternatively, cells were also exposed to 10 ng/ml or
100 ng/ml of bFGF or a combination of LPS 5 μg/ml, diclofenac 200 μM and
bFGF (Sigma-Aldrich).
2.3. RNA extraction and northern blot analysis
For each condition, cells were washed in PBS, directly lysed in the culture
dish by adding TRIZOL Reagent (Invitrogen) as recommended by the supplier
and kept at −80 °C until all samples were collected. For northern blots, 20 μg of
total RNA was denatured in formaldehyde/formamide and migrated in 1.5%
agarose gel containing MOPS (20 mM) and formaldehyde (17%). Nucleic acids
were transferred to Osmonics Nylon Transfer Membranes (Fisher Scientific) and
UV-fixed for 3 min. The membranes were hybridized with [α-32P] dCTP-
labeled apoD, hsp70, caveolin-1 or GAPDH cDNAs, exposed to Biorad Imaging
screen K and revealed with a PhosphorImager (Biorad Molecular Imager FX)
and Quantity One software (Biorad). For each value, the optical density
measured for each gene tested was divided by that of the GAPDH mRNA. The
ratio obtained from sparse cultures was given an arbitrary value of one.
2.4. TUNEL assay
Apoptosis was monitored by TUNEL reaction using the In situ cell detection
kit, fluorescein labeled (Roche, Mannheim, Germany) according to the
manufacturer's instructions. Cells were plated on 4 well-Sonic Seal Slides
(Nunc, VWR) at 50% confluency, allowed to recover 24 h then subjected to
stress conditions as described above. Results are expressed as percentage of
fluorescent apoptotic cells.
2.5. MTS/PMS viability test
Cell viability was measured using the CellTiter 96 AQueous Non-
Radioactive Cell Proliferation Assay (Promega) according to the manufacturer's
instructions. Cells were plated as above and the results are expressed as
percentage of proliferative cells.
2.6. BrdU incorporation
The proliferation assay was performed using colorimetric BrdU labeling and
detection kit I according to the manufacturer's protocol (Roche, Mannheim,
Germany). Results are expressed as BrdU incorporating cells relative to that of
growing unstressed cells.Table 1
Sites implicated in apoD transcription induction following LPS exposure
Element Sequence Position O
APRE-3 AACTTTTAGCCCCAGTT −681 to −665 (
NF-kB1 ACTGGTATCTCCCCT −656 to −642 (
NF-kB2 GGGGGCTGCCC −568 to −558 (
AP-1 TTGACTCAT −535 to −527 (
The primers used for mutagenesis of the region −816/−417 cloned upstream of the m
lower case.2.7. Beta-galactosidase staining of senescent cells
The β-galactosidase activity at pH 6.0, a known characteristic of senescent
cells, was used to measure senescence. Cells were plated as above and the results
are expressed as percentage of β-galactosidase expressing cells.
2.8. Construction and transfection of apoDh–GFP fusion protein
expression vectors
The human apoD coding sequence, including the signal peptide, was cloned
in frame in pEGFP-N1 and pEGFP-C1 vectors (BD Biosciences Clontech). The
construct was transfected in NIH/3T3 cells with Qiagen's Polyfect transfection
reagent as recommended by the supplier. Twenty-four hours later, cells were
rinsed twice with phosphate-buffered saline and culture mediumwas changed for
medium containing 10% serum supplemented with 5 μg/ml of LPS or low-serum
medium (containing 0.2% serum) or normal medium containing 10% serum.
2.9. Immunocytochemistry and cytochemistry
Cells were fixed with 4% paraformaldehyde 0, 3 or 6 days after stress
induction and stained with propidium iodide (Sigma-Aldrich) or bodipy
ceramide TR (Invitrogen). All fluorescent imaging was done at 40× magnifica-
tion using confocal microscopy. For control, cells were transfected with pEGFP-
N1 vector alone. For immunofluorescence staining, NIH/3T3 or U373MG cells
were grown on Labtek chamber slides (Fisher Scientific), subjected to stress
conditions as above and fixed with 4% paraformaldehyde for 10 min at room
temperature. After five washes with PBS, fixed cells were incubated in blocking
and permeabilization solution (3% serum from the host animal of the secondary
antibody and 0.2% Triton X-100 in PBS) for 1 h. Cells were sequentially
incubated with primary antibody (polyclonal anti-mouse apoD raised against the
bacterially expressed GST-fused mature mouse apoD, 1:50, Caro2 polyclonal
anti-human apoD raised against human apoD purified from mammary cyst fluid,
1:50, or 2B9 monoclonal anti-human apoD, 1:200 [28]) and then corresponding
fluorophore-labeled secondary antibodies (Cy3- and FITC-labeled anti-rabbit
IgG (Cedarlane laboratories limited), 1:100, for anti-human apoD and anti-
mouse apoD polyclonal antibodies respectively and FITC-labeled anti-mouse
IgG (Cedarlane laboratories limited), 1:200, for anti-human apoD monoclonal
antibody) for 1 h, respectively. Cells were washed five times with PBS and then
mounted with Slowfade Gold Antifade (Molecular Probes) before imaging. For
inhibition of protein secretion by brefeldin A treatment, apoDh–GFP transfected
cells were grown on chamber slides and subjected to stress conditions during
4 days. Cells were then treated with or without brefeldin A (5 μg/ml) (Sigma-
Aldrich) for 1 h and fixed 24 h later for confocal microscopy.
2.10. Human apoD promoter-luciferase constructs and mutagenesis
Heterologous luciferase (LUC) reporter gene constructs containing different
portions of the human apoD gene promoter were made by classic methods as
previously described [19]. The APRE-3, the two NF-kB and the AP-1 elements
present in region −816 to −471 were mutated by oligonucleotide-directed PCR
mutagenesis (Table 1). For that purpose, PCR-amplified −816/−471 portion ofrientation Primers used for mutagenesis
+) Forward: 5′-CTCAACTTTcgGCCaaAGTTGTTAGA-3′
Reverse: 5′-TCTAACAACTttGGCcgAAAGTTGAGA-3′
−) Forward: 5′-ACTGGTATCTaaaCTACACGTCTGGC-3′
Reverse: 5′-GCCAGACGTGTAGtttAGATACCAGT-3′
+) Forward: 5′-GAGAAGTTAGtttGCTGCCCAGG-3′
Reverse: 5′-CTGGGCAGCaaaCTAACTTCTC-3′
+) Forward: 5′-CAGCTTTGACTtgTAACCCTCGC-3′
Reverse: 5′-GCGAGGGTTAcaAGTCAAAGCTG-3′
inimal promoter −179/−4 are indicated. The mutated nucleotides are indicated in
Fig. 1. ApoD mRNA modulation under stress conditions is associated with
variations in proliferation, senescence and apoptosis. (A) ApoD mRNA
expression in NIH/3T3 cells after exposure to various stresses. Untreated
growing cultures (N) and serum-starved cultures (0.2%) are included as controls.
The following lanes are, respectively, RNA from cultures exposed to high
temperatures (Hs 42 °C and Hs 45 °C), low temperatures (Cs 32 °C and Cs
4 °C), hypo- and hyper-osmotic conditions (H2O and NaCl), metal salts,
hydrogen peroxide (H2O2 100 μM and 300 μM), lipopolysaccharide (LPS 2, 5
and 10 μg/ml), UV light (1 and 2 min) or camptothecin (CPT 5 and 10 μM).
Blots were hybridized with mouse apoD, hsp70 and GAPDH cDNAs. (B)
Apoptosis, viability and senescence were measured by the TUNEL assay, by the
MTS/PMS mitochondrial respiration assay and by the β-galactosidase activity,
respectively. Data are represented as mean±S.D. of at least three experiments.
Asterisk indicates statistical difference compared to normal conditions (unpaired
Student's t-test, *p<0.001).
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−179 upstream of the luciferase reporter gene in the pXP2 expression vector.
Eight complementary mutated primers and two primers from the vector were
used in two-step PCR (Table 1). Multiple mutants were constructed by the same
technique using sequential mutagenesis. All of the luciferase reporter constructs
were sequenced to confirm their integrity. Each construct was co-transfected in
NIH/3T3 cells with a β-galactosidase expression vector with Polyfect reagent.
After transfection, the cells were maintained in either LPS containing (5 μg/ml)
or LPS-free medium. The luciferase activity was analysed after 4 days, and the
results were normalized for the β-galactosidase activity.
2.11. Luciferase and β-Galactosidase assays
Cells were washed with PBS before adding 100 μl of Tris–HCl, 0.25 M, pH
7.8. Cells were then scraped with a cell lifter, transferred into microcentrifuge
tubes, lysed by three cycles of freeze–thawing and the lysates were stored at
−20 °C as described previously [19]. Luciferase assays were performed with a
Wallac 1404 luminometer using the conditions and buffers recommended by the
Luciferase assay system (Promega). β-Galactosidase assays were done as
follows: each sample (30 μl) was adjusted to a final concentration of 1 mM
MgCl2, 45 mM β-mercaptoethanol, 0.88 mg/ml o-phenyl-β-D-galactopyrano-
side, and 0.1 M sodium phosphate (pH 7.5) and incubated at 37 °C for 30 min.
Reactions were stopped by the addition of Na2CO3 to a final concentration of
625 mM, and the optical density was read at 420 nm. The results were
standardized by calculating promoter activity relative to that of the co-
transfected internal control plasmid pRSVβGAL. Each value is the average of at
least three independent experiments performed in triplicate.
2.12. Extraction of total and nuclear proteins
For total protein extraction, 2.5×105 cells were lysed in 10 μl lysis buffer
(50 mM Tris–HCl, pH 7.3, 150 mM NaCl, 5 mM EDTA, 0.2% Triton X-100,
and 10% CompleteTM protease inhibitors (Roche, Indianapolis, IN)). After 30-
min incubation at 4 °C, lysates were sonicated and cleared by 10 min of
centrifugation at 20,000×g at 4 °C. For nuclear protein extraction, cells were
washed twice with PBS and lysed in a solution containing 10 mM Tris, pH 7.4,
10 mM NaCl, 3 mM MgCl2, 0.1 mM EDTA, 1 mM phenylmethylsulfonyl
fluoride and 0.5% Nonidet P-40. Nuclei were pelleted by centrifugation at
2000×g for 2 min and washed once in the same buffer to remove residual
cytoplasmic proteins. After removal of cytoplasmic proteins, cell nuclei were
lysed at 37 °C for 3 to 5 min in a hyperosmolar neutral-pH solution with 0.5 M
NaCl, 50 mM MgCl2, 2 mM CaCl2, 10 mM Tris buffer, 100 U of DNase I/ml,
and 10% CompleteTM protease inhibitors. The protein concentration was
determined spectrophotometrically at 590 nm using the Bio-Rad protein assay
reagents (Bio-Rad Laboratories). All extracts were stored at −70 °C.
2.13. Immunoblotting
Protein extracts (10 μg) were heated for 10 min at 70 °C before being loaded
onto a 12% SDS-polyacrylamide gel. A prestained size marker (Biorad
prestained SDS-PAGE standard, low range) was included in each run. The gel
was subjected to electrophoresis for 1 h at 40 mA and then transferred by
electroblotting to a polyvinylidene difluoride (PVDF, Millipore) membrane for
45 min at 300 mA. Membranes were blocked for 1 h at room temperature with
blocking buffer (PBS containing 0.2% Tween 20 and 5% skimmilk powder) and
incubated for 1 h at room temperature with 1:1000 anti-human apoD (Caro2
polyclonal antibody), 1:1000 anti-GFP (Chemicon) or 1:4000 anti-GAPDH
(Calbiochem) or overnight at 4 °C with 1:1000 anti-mouse apoD polyclonal
antibody in blocking buffer. Subsequently, the blots were incubated under gentle
agitation at room temperature with a secondary horseradish peroxidase
conjugated anti-rabbit antibody (GE Healthcare) diluted 1:5000 in blocking
buffer. The blots were developed using the enhanced chemiluminescence
method (Amersham-Pharmacia) with X-ray film.
2.14. Statistical analysis
Statistical significance of the apoD mRNA expression, apoptosis, cell
viability and senescence levels in cells subjected to different stress incomparison with normal conditions was evaluated using an unpaired Student's
t-test or a one-way ANOVA. Statistical differences between the different
constructs used for the identification of LPS responsive elements in the apoD
promoter were assessed by ANOVA. Differences identified by ANOVA were
pinpointed by the Turkey–Kramer multiple comparison test.3. Results
3.1. ApoD expression in response to cellular stress
Previous studies have shown that apoD mRNA is induced in
cell cultures under specific conditions [for review, see 6, 43]
and that its expression could be part of an antioxidant defense
system [51]. Tatil, the plant apoD homolog is upregulated in
response to temperature and water stress [52]. However, in
mammalian cells, no data are available regarding temperature
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between apoD and apoptosis, oxidative stress or inflammation
has been reported. To analyze this aspect, we measured apoD
mRNA expression in murine NIH/3T3 fibroblasts exposed to
various stresses (Fig. 1A). Our team previously used these cells
since they express apoD in a fashion similar to glial, epithelial
and primary fibroblasts [19]. Endogenous apoD mRNA
expression was very low in growing cells and in cells exposed
to heat and cold shocks of high (Hs 45 °C, Cs 4 °C) or low (Hs
42 °C, Cs 32 °C) intensity. ApoD mRNA expression was also
very low in cells grown in hypo- or hyper-osmotic conditions.
Since the apoD promoter contains one putative metal
responsive element [19], a combination of metals was tested.
However, no change in apoD mRNA levels was detected. For
these conditions, longer exposures and recovery times were
also tested and no further increase of apoD expression was
observed. In contrast, H2O2 and UV light induced apoD
transcripts accumulation in a dose-dependent manner (Fig. 1A).
This was also observed with Rose Bengal another inducer of
oxidative stress (data not shown). Lipopolysaccharide (LPS)
also induces a dose-dependent response. Finally, camptothecin,
an apoptosis inducer, had no effect on apoD mRNA expression.Fig. 2. ApoD mRNA expression after H2O2 treatment is concentration-
dependent. (A) Total RNAs were isolated from NIH/3T3 untreated (N) or treated
with increasing concentrations of H2O2. Serum starved cells are included as
control. Hybridization was performed with mouse apoD, caveolin-1 and
GAPDH cDNAs. (B) Quantification of apoptosis, viability and senescence after
H2O2 exposure was performed as in Fig. 1B. Data are represented as mean±S.D.
of at least three experiments. Asterisk indicates statistical difference compared to
normal conditions (unpaired Student's t-test, *p<0.001).
Fig. 3. ApoD mRNA expression after LPS treatment and relation with infla-
mmation and proliferation. (A) NIH/3T3 cells were exposed to LPS (5 μg/ml)
during the indicated number of days. Northern analysis was performed with total
RNAs probed with mouse apoD and GAPDH cDNAs. (B) ApoD expression in
cells treated with LPS diclofenac or basic fibroblast growth factor (bFGF) for
4 days. Untreated growing cells (N) and serum-starved cells (0.2%) were
included as controls. Northern analysis was performed with total RNAs probed
with mouse apoD and GAPDH cDNAs. (C) Analysis of proliferation by BrdU
incorporation in cells treated as in B. Data are represented as mean±S.D. of at
least three experiments. Asterisk indicates statistical difference compared to
normal conditions or as indicated (one-way ANOVA, *p<0.001).As expected, hsp70 is increased in the temperature, osmotic,
metal, UVand H2O2 treatments revealing that the stress applied
were effective. However, hsp70 is not activated by LPS. For
comparison, serum starved cells were included and they show a
substantial apoD mRNA increase as previously reported [19]
(Fig. 1A).
It is interesting to note that, with the exception of LPS, those
conditions that cause an apoD transcript accumulation also
decrease cell proliferation (Fig. 1B). In fact, growing cells and
cells exposed to temperature or osmotic shocks, metals or low
concentrations of H2O2 (100 μM) maintain a proliferative rate
above 58% and a low level of apoD mRNA expression. At
higher H2O2 concentration or long UVexposure, the results may
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apoptosis. However, no apoD mRNA induction was observed
under treatments with various concentrations and time expo-
sures of camptothecin, (Fig. 1A). Moreover, senescence, which
is observed at high H2O2 concentration (300 μM), has alreadyFig. 4. Identification of LPS responsive elements in the apoD promoter. (A) A series o
the 5′-flanking regions of the apoD gene promoter. (B) Site-directed mutagenesis of
mutated alone or in combination with the others in a construct containing the −816/−
The mutated sequences are summarized in Table 1. All constructs were transfected in
(gray bars) 5 μg/ml LPS. Luciferase activities were assayed 4 days after transfection. T
that of cells without LPS. Each value represents the mean±S.D. of at least three e
***p<0.001). Letters at the right of the induction numbers represent statistical signbeen reported for its ability to induce apoD expression [18].
Finally, the conditions presenting the best induction, LPS
exposure and serum starvation, both have apoptosis levels
comparable (4% to 6% in LPS) or only slightly superior (12% in
serum starvation) to those seen in growing cells (6%). Thus, ourf luciferase reporter constructs was made that contained progressive deletions of
APRE-3, NF-kB1, NF-kB2 and AP-1 responsive elements. Each element was
471 region of the promoter cloned upstream of the minimal promoter −179/−4.
to NIH/3T3 cells, which were maintained in media with (black bars) or without
he induction represents the ratio of luciferase activity in cells treated with LPS to
xperiments performed in triplicate (One-way ANOVA, *p<0.05, **p<0.01,
ificance; different letters indicate statistically different-fold induction.
Fig. 5. Effects of LPS exposure and serum starvation on the intracellular
localization of endogenous apoD and apoDh–GFP. NIH/3T3 cells were kept in
normal growing conditions (N), treated with 5 μg/ml LPS or grown in low-
serum medium (0.2%) for 0, 3, or 6 days and then subjected to Western blot
analyses. Total (A), nuclear (B), and secreted (C) fractions of endogenous apoD
and apoDh–GFP were detected with an anti-mouse apoD (apoDm) and an anti-
GFP antibody, respectively. An anti-GAPDH antibody was included as a loading
control. Each experiment was repeated at least 3 times.
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mRNA accumulation is cellular growth arrest rather than
apoptosis (Fig. 1B).
3.2. ApoD expression under oxidative stress correlates with
decreased cell proliferation
To further assess the contribution of oxidative stress in the
apoD mRNA expression observed in Fig. 1A, NIH/3T3 cell
cultures were exposed to increasing concentrations of H2O2.
ApoD transcripts accumulate from 100 μM to 300 μM in a dose-
dependent manner (Fig. 2A). This apoD increase correlates well
with a decrease in cell viability rather than an increased apoptotic
rate (Fig. 2B). Indeed, no apoD accumulation is detected in low
H2O2 concentrations already documented as being mitogenic
(5 μM to 30 μM) [53] nor in the highly apoptotic 500 μM
concentration. ApoD induction could also be caused by an
increased senescence, which reach 40% in the 300 μM dose,
although this situation is closely linked to a growth arrested state.
Caveolin-1 is included as a control since its expression has beenFig. 6. Intracellular localization of apoD after exposure to LPS or serum starvation.
apoD-coding region fused to GFP (apoDh–GFP) and treated with 5 μg/ml LPS (m–
(a–c; e–g; m–o) or 6 (i–k; q–s) days after normal or stress conditions at 40× magn
(GFP) indicates the position of apoDh–GFP, whereas the red fluorescence (propi
localization of apoDh–GFP is indicated by yellow in the merged images. Results w
polyclonal mouse apoD antibody in the same stress conditions (d, h, l, p, t). (B) G
Bodipy ceramide (c) in NIH/3T3 cells transfected with apoDh–GFP and kept 3 d
Immunofluorescence staining of human glioma cell line U373MG using a Caro2 po
serum starvation (b) or LPS (5 μg/ml; c).demonstrated to be upregulated by H2O2 treatment [54]. This
inductive effect of H2O2 on apoD expression was also observed
at lower doses, in a dose-dependent manner with HepG2, HeLa,
293, U373MG and U87 cultures (data not shown) indicating that
the human apoD is subjected to the same regulation.
3.3. ApoD expression is associated with pro-inflammatory
stimuli
Since the inductive effect of LPS on apoD transcription is
dose-dependent (Fig. 1A), we decided to determine whether this
effect was time-dependent. LPS induces a time-dependent
transcript accumulation during 6 days and reaches a plateau
(Fig. 3A). The decrease at day 7 coincided with a partial
detachment of the cell monolayer. This inductive effect of LPS on
apoD expression was also observed with HepG2, HeLa, 293,
U373MG and U87 cultures although the LPS concentrations
required to induce apoD expression were lower (data not shown).
Besides its pro-inflammatory properties, LPS has been
extensively used as a potent inducer of proliferation and cyto-
kine production in human T-lymphocyte, monocytes/macro-
phages, vascular cells, polymorphonuclear cells, and even B
lymphocytes [55]. To determine which of the two LPS
properties is responsible of apoD induction, we analyzed
another proliferative molecule, basic fibroblast growth factor
(bFGF) and an anti-inflammatory drug, diclofenac. Diclofenac
has been previously used in fibroblast cultures to oppose
inflammatory effects of LPS and it has an anti-proliferative
effect [56]. The bFGF failed to induce apoD (Fig. 3B) whereas
LPS and serum starvation showed a good increase in apoD
mRNA expression, as expected (Figs. 1A and 3A). Further-
more, the proliferative effect of LPS was similar to that of bFGF
with a 2 to 3 fold increase as documented by BrdU incor-
poration (Fig. 3C). The addition of diclofenac to the culture
media slightly increases apoD transcript accumulation. This is
most likely due to its anti-proliferative properties. Moreover,
diclofenac decreases the proliferative action of bFGF but has no
further influence on apoD transcription (Fig. 3B and C). More
importantly, diclofenac decreases the LPS-induced apoD
expression indicating that the pro-inflammatory rather than
the mitogenic properties of LPS are responsible for activating
apoD expression (Fig. 3B and C).
3.4. ApoD expression is associated with specific elements in the
promoter
The apoD promoter contains an abundance of potential
regulatory elements. It has already been established that a pair(A) Confocal microscopy analysis of NIH/3T3 cells transfected with the human
o; q–s) or 0.2% serum medium (e–g; i–k). All fluorescent imaging was done 3
ification and each experiment was done at least three times. Green fluorescence
dium iodide; PI) indicates the position of the nucleus. The extent of nuclear
ere confirmed by immunofluorescence staining of untransfected cells using a
FP (a), Bodipy TR ceramide (b) and overlaid fluorescence of apoDh–GFP and
ays in normal conditions before being treated with Bodipy TR ceramide. (C)
lyclonal human apoD antibody. Normal cells (a) were exposed during 6 days to
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pyrimidine stretch are the major determinants of growth
arrest-induced apoD gene expression [19]. To identify those
elements that regulate apoD expression in fibroblast cultures
exposed to LPS, we used deletion mutants containing differentportions of the apoD promoter (−1176 to −4) upstream of the
luciferase reporter gene.
With the construct containing the entire promoter region
(−1176 to −4), the LPS treatment resulted in an 8-fold induction
of promoter activity when compared to normal conditions (Fig.
962 S. Do Carmo et al. / Biochimica et Biophysica Acta 1773 (2007) 954–9694A). This induction is significantly reduced to 3-fold when
region −1176 to −558 is absent and totally abolished when only
the minimal promoter is present (−179). The deletion of eitherregion −352/−179 or −473/−191 resulted in a small decrease in
induction suggesting a negligible contribution of APRE2
elements in response to LPS. This is further confirmed when
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only by one APRE2 element. Furthermore, the deletion of
portions −558/−352 and −558/−179 resulted in a drastic
reduction of induction (3- and 2-fold respectively) that under-
lines the importance of AP1 in the LPS response. The induction
level can be greatly enhanced by the addition of the AP-1
element (compare deletions −558/−179 and −473/−191).
Although important, the AP-1 element alone is insufficient to
restore the apoD induction by LPS. Thus, constructs −558 and
−548/−321 still display only a 3-fold induction compared to
−1176 suggesting that region −1176/−548 is at least as
important as the AP-1 element. This region contains two AP2,
an APRE3 and two NF-kB responsive elements. Again, this
region alone is unable to restore completely the LPS induction as
shown by deletion −558/−179 and construct −816/−597. Thus,
it appears that AP-1 cooperates with NF-kB and possibly with
APRE3, as suggested by construct −676/−471 and deletion
−473/−191, to induce apoD expression under inflammatory
conditions. Finally, comparison of deletion −1052/−558 with
fragment −558 reveals the weak importance of the third NF-kB
responsive element at position −1104.
Another construct was thus created that includes all the
elements important to LPS response. It contains the region
−816/−471 placed upstream of the minimal promoter −179 and
presented an activity comparable to that of the −1176/−473
region of the promoter (Fig. 4A). Mutational analysis of the
fragment −816/−471 (Fig. 4B) reveals that each of the APRE3,
NF-kB and AP1 elements is important to LPS response and
mutagenesis of APRE-3 or NF-kB1 or NF-kB2 is sufficient to
abolish apoD response to LPS while inactivation of AP-1 only
reduces the induction by half. Inactivation of NF-kB1 or NF-
kB2 reduces apoD expression both in normal conditions and in
presence of LPS. This phenomenon was also observed with the
NF-kB element located at position −1104 (compare deletion
−1052/−558 with −558 construct in Fig. 4A). Mutation of the
APRE-3 increases significantly basal transcription and prevents
LPS-induced transcriptional induction. When looking at double
and triple mutants (Fig. 4B), the AP-1 mutation counteracts the
effect of either NF-kB mutations but not both suggesting that
the interaction between one NF-kB and the AP-1 element relies
on the presence of the other NF-kB. This is clearly illustrated
with the double mutants mNF-kB1, mAP-1 and mNF-kB2,
mAP-1. However, AP-1 mutation cannot disable the APRE-3
mutation effect although the promoter activity was reduced in
both conditions. AP-1 seems to have a different effect on
APRE-3 depending on the NF-kB mutations. When mutated
AP-1 and APRE-3 sites are combined with a mutated NF-kB1
element, the basal promoter activity was increased whereas
LPS-stimulated activity was not. This was not the case when the
AP-1 and APRE-3 mutations were combined with a mutated
NF-kB2 element.Fig. 7. Internalization of exogenous human apoD or apoDh–GFP. (A) Immunofluor
human apoD antibody. Staining was performed 3 days after the addition of human apo
g–i) or in LPS (5 μg/ml; j–l) conditions. As a control, staining was conducted on ce
indicates the position of human apoD, whereas the red fluorescence (propidium iodid
human apoD is indicated by yellow in the merged images. (B) Confocal imaging of ex
GFP was added to cells in normal (a–c) or stress conditions (d–i) during 6 days.3.5. ApoD protein localization is altered by serum starvation
and LPS treatment
It is now clear that apoD transcription is modulated by
specific stress signaling pathways. We then verified the protein
induction and localization after LPS exposure and serum
starvation-induced growth arrest. For this purpose, an expres-
sion vector containing the entire human apoD coding sequence,
including the signal peptide, fused to the N-terminal end of the
fluorescent GFP protein (apoDh–GFP), was transfected and the
fusion protein was followed by western blot analysis and
confocal imaging in stressed and unstressed cells (Figs. 5 and
6). As already observed with the transcripts (Figs. 1A and 3A),
in total cell extracts, the endogenous mouse apoD increases in a
time-dependent manner after exposure to those stresses as
detected with a polyclonal antibody against mouse apoD (Fig.
5A; apoDm). However, the protein increase was not as high as
for the mRNA and after 6 days of serum starvation, the protein
accumulation was 3.5 fold compared to 10 fold for the mRNA
[19]. Similarly, after 6 days of LPS exposure, apoD transcript
and protein levels are increased 7 fold and 1.5 fold, respectively.
It is noteworthy that in addition to its accumulation in the cell,
apoD is also found in the nucleus after stress exposure (Figs. 5B
and 6). Interestingly, the nuclear apoD has a molecular mass
similar to that of the secreted protein (≈55 kDa for apoDh–GFP
and 30 kDa for endogenous mouse apoD). Finally, it is also
clear that apoD is secreted both in normal and LPS conditions.
However, endogenous apoD is no longer secreted after 3 and
6 days of serum starvation (Fig. 5C). When growth arrested
cells are reallowed to proliferate by the addition of 10% serum
to the culture medium, the endogenous mouse apoD returns to
basal levels, is no longer found in the nucleus and is secreted
again in the extracellular space (data not shown). In the same
way, apoD was no longer found in the nucleus when the LPS
treatment was interrupted. These changes in localization are
also obvious in immunoblots with anti-GFP antibodies (Fig. 5).
In total cell extracts (Fig. 5A), apoDh–GFP is detected in all
conditions as expected since it is transcribed from the CMV
promoter. In nuclear extracts, however, apoDh–GFP is absent in
normal conditions, most likely because it is secreted but it is
detected after 3 and 6 days after LPS exposure and serum
deprivation (Fig. 5B). This localization is directly correlated
with that of the endogenous apoD.
The subcellular localization of apoDh–GFP fusion protein
was further examined using confocal fluorescence microscopy.
In unstressed normal cells, (Fig. 6A, a–c), apoD is found in
the perinuclear area. This localization is consistent with the
Golgi apparatus as demonstrated by overlaid fluorescence of
GFP and Bodipy TR ceramide (Fig. 6B, a–c). Similar to
immunoblotting results, no apoDh–GFP is present in the
nucleus as established by the lack of colocalization with theescence staining of cells exposed to purified human apoD using a monoclonal
D (200 ng/ml) to the culture media of cells in normal (d–f), in low serum (0.2%;
lls without the addition of human apoD (a–c). Green fluorescence (anti-apoDh)
e; PI) indicates the position of the nucleus. The extent of nuclear localization of
tracellular apoDh–GFP. Conditioned media from cells transfected with apoDh–
Fig. 8. Effect of exogenous human apoD on endogenous apoD expression,
apoptosis and proliferation. Induction of apoD mRNA (A) and protein (B)
expressions was tested 3 days after the addition (+) or not (−) of 200 ng/ml of
human apoD to the culture media. Northern analysis was performed with total
RNAs probed with mouse apoD and GAPDH cDNAs. Western immunoblot
analysis for human and mouse apoD protein was performed on total cell lysates
and is representative of two separate experiments. Apoptosis (C) and
proliferation (D) levels were determined by TUNEL assay and by BrdU
incorporation, respectively in the presence (+) or absence (−) of 200 ng/ml of
human apoD in growing cells compared with serum starved (0.2%) and LPS
treated (5 μg/ml) cultures. Each bar represents the mean ratio of fluorescent
apoptotic cells±SD in each condition of three separate experiments performed
in triplicate. Asterisk indicates statistical difference compared to conditions
without addition of human apoD (unpaired Student's t-test, *p<0.001).
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3 days of serum starvation or LPS treatment, this localization is
altered. ApoDh–GFP distribution is extended in the cytoplasm
and becomes visible in the nucleus (Fig. 6A, e–g and m–o).
Interestingly, during serum starvation, apoDh–GFP appears as
a dotted localization in the cytoplasm (Fig. 6A, e). The nuclear
localization of apoDh–GFP intensifies after 6 days of stress
exposure (Fig. 6A, i–k and q–s) as showed by merged images
with PI staining of the nucleus. We also produced the reverse
fusion protein containing the human apoD coding sequence
linked to the C-terminus of GFP (GFP–apoDh). Since the
apoD peptide signal is now in the middle of the fusion protein,
the fluorescence patterns indicated a subcellular distribution
identical to the GFP alone (results not shown). The subcellular
distribution of endogenous apoD was also probed with a
polyclonal mouse apoD antibody. Confocal microscopy con-
firmed that apoD is perinuclear in normal conditions (Fig. 6A,
d) and translocates to the nucleus as stress is prolonged (Fig.
6A, h, l, p, t). Together, these results indicate that apoD drives
GFP into the nucleus. Finally, immunofluorescence staining of
human glioma cell line U373MG using a polyclonal human
apoD antibody shows that the nuclear localization pattern is not
restricted to NIH/3T3 cell line. As a matter of fact,
fluorescence is clearly concentrated in the nucleus of cells
exposed to serum starvation or LPS conditions during 6 days
but appears diffuse in normal conditions.
3.6. Exogenous apoD enters cells and affects cellular status
ApoD is a glycosylated and secreted protein. Its presence in
the nucleus might be explained by its re-entry in the cell after
secretion and its transport to the nucleus. It has already been
shown that human apoD, purified from breast cyst fluid, enters
ovine vascular smooth muscle cells when added to the culture
medium [40]. Moreover, it interacts specifically with the
cytoplasmic portion of the leptin long form receptor Ob-Rb
[57]. In the same way, human apoD, purified from cyst fluid,
also enters NIH/3T3 cells when added to the culture medium,
as detected with human apoD specific antibody (Figs. 7A and
8B). Moreover, the human apoD localization is dependent on
cellular status. In normal growing cells, human apoD is
detected in the cytoplasm but not in the nucleus (Fig. 7A, d–f).
In comparison, in serum starved and LPS exposed cells, human
apoD accumulates in the cytoplasm but also in the nucleus as
demonstrated by merged images of the fluorescence of the anti-
human apoD antibody and the nuclear marker PI (Fig. 7A, g–
l). However, in absence of human apoD, no signal could be
detected demonstrating the high specificity of the antibody
towards human apoD (Fig. 7A, a–c). Similarly, when
conditioned media from apoDh–GFP transfected cells was
added to cells that were further exposed to normal or stress
conditions during 5 days, fluorescence could be detected in the
cytoplasm of normal growing cells (Fig. 7B, a–c). In serum
starved and LPS exposed cells, the fluorescence accumulated
inside the nucleus as demonstrated by a strong colocalization
with nucleus staining (Fig. 7B, d–i). The weaker nuclear
localization obtained with the addition of human cyst fluidapoD in comparison with the addition of apoDh–GFP is
explained by the fact that an earlier time point is shown (3 days
and 6 days post-treatment respectively).
The ability of apoD to enter the cell and its nucleus also
suggests an implication in nuclear processes such as transcrip-
tion activation, cell cycling or apoptosis. We investigated
further the effect of extracellular apoD in growing and stressed
mouse fibroblast cultures using antibodies that recognize
specifically the human protein. The presence of human apoD
has no influence on apoD mRNA or mouse protein expression
(Fig. 8A and B), although, it can modulate cell proliferation and
apoptosis. When human apoD is added to growing cells, we
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proliferation. Similarly, the addition of human apoD to LPS-
treated cells does not affect the apoptotic rate but further
increases the proliferation level already enhanced by LPS
addition. However, when applied to serum-starved cells, human
apoD had no effect on cell proliferation but increased apoptosis
(Fig. 8C and D).
3.7. Nuclear apoD is derived from secreted protein
To further confirm that the presence of apoD in the nucleus
under stress conditions is due to a reentry of the secreted
protein, apoDh–GFP transfected cells were subjected to stress
and to brefeldin A (BFA) treatment. Brefeldin A disrupts the
structure and function of the Golgi apparatus. Immunoblot
analysis of the conditioned media from apoDh–GFP transfected
cells confirmed the presence of the secreted fusion protein
(55 kDa) in both normal and LPS-treated cells but not in serum
starved cultures (Figs. 5C and 9A). When BFA was added,
apoDh–GFP disappeared from the conditioned media in both
normal and LPS conditions (Fig. 9A) confirming that the
apoDh–GFP detected originated from secretion via the Golgi
apparatus. As expected, this inhibition of apoDh–GFP secretion
abolished the nuclear localization of apoDh–GFP but caused an
accumulation in the cytoplasm both in serum starvation and in
LPS conditions (Fig. 9B). All together, these results strongly
suggest that the nuclear apoD is derived from the secreted
protein. This conclusion can be extended to the endogenousFig. 9. Intracellular localization of apoDh–GFP in brefeldin A exposed cells.
ApoDh–GFP transfected cells were subjected to growing (N), serum starved
(0.2%) and LPS (5 μg/ml) conditions during 4 days. (A) Western immunoblot
analysis for human apoDwas performed on the culturemedia of cells treated with
or without BFA (5 μg/ml) for 1 h and processed 24 h later for immunoblotting.
(B) Confocal fluorescence imaging of cells transfected with apoDh–GFP,
exposed to stress conditions and treated or not with BFA as in panel (A).protein since all localization studies (Figs. 5 and 6) show that
apoDh–GFP behaves identically to endogenous apoD.
4. Discussion
In this study, we demonstrate that some but not all stress
conditions activate apoD expression. Temperature, osmotic
pressure, metal exposition and pro-apoptotic agents such as
camptothecin did not affect apoD transcription. However,
classical inducers of oxidative stress, H2O2, Rose Bengal and
UV light did induce apoD mRNA accumulation in a dose-
dependent manner. This response was very closely associated
with a decrease in cell proliferation and viability as demon-
strated with increasing concentrations of H2O2. Indeed, induced
apoD expression was observed specifically at those H2O2
concentrations that caused growth arrest. This strongly suggests
that the capacity of some specific stresses to trigger apoD
expression is more related to their capacity to activate growth
arrest pathways. The relation between apoD and growth arrest is
well established. When analyzed in cell cultures, apoD
induction seems always inversely correlated to cell proliferation
[18–26].
This study is also the first to our knowledge that establishes a
relation between apoD expression and inflammation. Indeed,
the only stress that increased apoD without inhibiting cell
proliferation was LPS. This molecule, derived from the outer
membrane of Gram-negative bacteria, is well documented as
being both a mitogen and a pro-inflammatory agonist in several
cell types participating to inflammatory responses, including
fibroblasts [58–60]. It is also capable to induce oxidative stress
through the activation of NADPH oxidase and antioxidant
enzymes. In spite of this, we believe that apoD expression is
related to inflammatory pathways because of the capacity of
diclofenac to reverse the LPS-associated induction. Our results
also show that the LPS function on the apoD expression is
mediated at the promoter level, through the APRE-3, NF-kB
and AP-1 binding sites. AP-1 and NF-kB are well documented
as regulators of numerous genes involved in immune and
inflammatory responses [61]. In different cell and promoter
contexts, AP-1 binds DNA as Jun/Jun homodimers or Jun/Fos
heterodimers and alters gene expression in response to growth
factors, cytokines, oxidative stress, and phorbol esters [62].
Less information are available concerning acute-phase respon-
sive elements (APRE) having a consensus sequence similar to
the one present on the apoD promoter. Some studies reported
that APREs have an important role during inflammation and
infection and to bind IL-1α [63], IFN-γ [64], IL-6 [65] and NF-
kB1 isoforms [66]. The APRE could also bind C/EBPβ which
is mobilized upon LPS administration in mice. C/EBPβ is an
important regulator of genes involved in immune and
inflammatory responses and has been shown to bind the IL-6
gene promoter as well as several other acute-phase and cytokine
genes [67]. This pathway is not yet fully understood but allows
the production of prostaglandin E2 [68], a member of the pro-
inflammatory eicosanoids family. Interestingly, arachidonic
acid, the preferential ligand for apoD, is the dominant substrate
for eicosanoid synthesis [69]. In addition to C/EBPβ, the APRE
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roles in cell differentiation, proliferation, survival, and angio-
genesis promotion.
The accumulation of apoD under growth arrest and in
presence of LPS is also observed at the protein level. However,
the protein accumulation is more modest than that of the mRNA.
Our results clearly show for the first time that apoD subcellular
localization undergoes modifications upon stress exposure: it is
mainly secreted and found perinuclear in the Golgi apparatus
under basal conditions but accumulates in the cytoplasm and the
nucleus in stress conditions. Perinuclear localization of apoD has
been reported in oligodendrocyte precursor-like cells and
astrocytes of mouse brain of Niemann–Pick type C disease
model [71] and in vascular smooth muscle cells (VSMC) after
wounding [72]. The accumulation of apoD in the cytoplasm and
its translocation to the nucleus when growth arrest or pro-
inflammatory stimuli are applied was supported by several
independent experimental approaches. This included colocali-
zation of apoDh–GFP fusion constructs with DNA and Golgi
markers, immunocytochemistry of the endogenous protein, and
cell fractionation. Thus, immunoblotting of apoDh–GFP
transfected cells confirms that, upon serum starvation and LPS
treatment, there is an accumulation of apoD both in the cell and
in the nucleus. No detectable secretion in the extracellular space
was obtained in growth-arrested cells although easily detectable
in the extracellular space upon LPS treatment. The experiment
presented the advantage that we could follow the endogenous
mouse apoD and the exogenous human apoD linked to GFP.
Interestingly, both the mouse and human apoD behave similarly,
suggesting a common response pattern upon stress exposure
including similar pathways for nuclear transport.
Nuclear apoD may have several possible sources. It is
unlikely that apoD enters the nucleus by passive diffusion since
the fusion protein used in our study was generated by fusing
EGFP to the C-terminus of the entire coding region of human
apoD. The molecular mass of the resulting fusion protein is
≈55 kDa and therefore, it cannot enter the nucleus by diffusion.
Furthermore, apoD does not contain any common putative
nuclear localization signal (NLS) that could direct its transloca-
tion to the nucleus. Still, the binding of apoD to a
transmembrane receptor or a protein containing a NLS cannot
be excluded. Retrograde trafficking from ER to the nucleus is a
more plausible mechanism of translocating the intracellular
apoD from cytoplasm to the nuclear compartment. It has been
suggested that misfolded proteins that would classically
undergo degradation in the ER can be back-translocated from
the ER to the cytoplasm. However, if misfolding occurs, it is not
the consequence of the overexpression of the apoDh–GFP since
a similar localization of endogenous apoD was found in cells
transfected or not with the apoDh–GFP construct. Misfolding
could then be associated with the stress itself. In spite of this, we
provided evidences that nuclear apoD originates from the
extracellular compartment. Indeed, as a glycoprotein harboring
a peptide signal, apoD should be entirely secreted. Its presence
within cells exposed to specific stress suggests a protein re-
uptake, most likely by an endocytosis-dependent pathway, and
transport to the nucleus. This is in agreement with severalobservations: (1) the apoD present in the nucleus has a mole-
cular mass similar to that of the secreted protein; this would not
be the case if apoD had bypassed the Golgi and ER
glycosylation (2) apoDh–GFP is secreted as well as localized
in the nucleus; (3) when untransfected stressed cells (LPS
exposed or serum starved) are exposed to conditioned media
containing apoDh–GFP, the fusion protein is translocated to the
nucleus; (4) inhibition of protein secretion by BFA abolishes the
nuclear presence of apoDh–GFP, whereas it increases its
cytoplasmic content. Thus, apoD nuclear localization is
dependent on the functional Golgi apparatus; (5) human
apoD, purified from cyst fluid, is internalized in normal and
stressed cells but translocation to the nucleus is observed only
after stress; (6) finally, there is accumulating evidence that
secreted proteins are present in the nucleus under specific
circumstances. The fact that apoD is found in the nucleus of
serum starved cells although we could not detect its presence in
the media may appear as a contradiction but we cannot rule out
that very low levels of apoD are secreted and immediately
reabsorbed under these conditions. Indeed, the media was only
concentrated twice before analysis.
Even though, apoD is translocated differentially in normal
and stress conditions, its possible function in the cells remains
to be determined. The data obtained by confocal imaging and
immunoblotting of apoDh–GFP transfected cells and cells
exposed to exogenous human apoD suggest that, in normal
growing cells, apoD is modified in the Golgi apparatus and
secreted before reinternalization in the cytoplasm, possibly
transporting one of its ligand. The exposition of cells to
exogenous apoD followed by its internalization results in an
increased proliferation and points to an interaction of apoD or
its ligand or both with early targets of proliferative signals. The
function of apoD in the nucleus during stress is less clear. Its
accumulation in the nucleus of both serum starved and LPS
treated cells raised the possibility that it may regulate gene
expression directly or indirectly. In particular, it suggests a role
for apoD in the balance between apoptosis and cell prolifera-
tion. This balance might be dependent of the interaction of apoD
or its ligand or both with cell-cycle regulators that affect both
the proliferative and non-proliferative processes. Consequently,
the addition of exogenous apoD has a strong incidence on
cellular proliferation in LPS treated cells but apoptosis is
observed when added to growth-arrested cells. Both mitogenic
and growth arrest conflicting signals are known to initiate apo-
ptosis as this could be the case in growth arrested cells treated
with purified apoD. Yet, exogenous apoD does not influence
endogenous apoD protein or mRNA expression, excluding the
possibility of self-regulation.
Inflammation, oxidative stress and apoptosis are part of many
if not all the pathological situations where apoD is found
increased. Chronic inflammation is associated with certain
metabolic diseases such as non-insulin-dependent diabetes
mellitus type II and metabolic syndrome X (for review, see
[6,43]). There is also an emerging consensus of the inflamma-
tory and/or oxidative stress hypothesis of Alzheimer's disease,
multiple sclerosis, schizophrenia, bipolar disorder, traumatic
brain injury and other neuropathologies [30,44,73]. Moreover,
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expression [37,74,75]. Thus, it might be difficult to distinguish
the incidence of each of these pathways on apoD induction since
most of them are intimately linked. However, the present study
suggests that those conditions responsible for apoD expression
are more related to an antiproliferative and inflammatory signals
than to oxidation and apoptosis. It remains to be determined
whether apoD accumulation in inflammation is protective or
detrimental. ApoD could be part of the protective component of
a mild inflammation, particularly at the neuronal level. It could
also trap inflammatory mediators. In particular, apoD could trap
arachidonic acid, which is released from the cellular membrane
after inflammatory stimuli, and prevent its subsequent conver-
sion in pro-inflammatory eicosanoids.
In conclusion, apoD induction is specific to ongoing cellular
stress. Only pathological and/or stressful situations tested here
having an inflammatory or growth arrest component have the
capacity to increase apoD expression. We have provided some
lines of evidence indicating that these stresses induce a
displacement of apoD localization and that the nuclear apoD
is derived from the secreted protein. ApoD binds several quite
different molecules. Within the cell, apoD could have many
functions such as the transport of specific molecules to the
various compartments and evacuation of toxic metabolites. It
could also play a role in the modulation of signal transduction
pathways and in the regulation of nuclear processes such as
transcription activation, cell cycling and apoptosis. More
studies are needed to identify potential target genes of apoD
and to elucidate the molecular events that trigger its cell entry
and nuclear translocation.
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